DC8A Stock Overview A biopharmaceutical company, develops medicines based on its epigenetic regulator program. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
DURECT Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for DURECT Historical stock prices Current Share Price US$0.84 52 Week High US$1.61 52 Week Low US$0.43 Beta 0.93 1 Month Change -7.65% 3 Month Change -27.78% 1 Year Change 104.11% 3 Year Change -90.06% 5 Year Change -97.07% Change since IPO -99.47%
Recent News & Updates
Third quarter 2024 earnings released: US$0.14 loss per share (vs US$0.11 loss in 3Q 2023) Nov 16
New major risk - Revenue and earnings growth Nov 14
DURECT Corporation to Report Q3, 2024 Results on Nov 13, 2024 Nov 07
Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.46 loss in 2Q 2023) Aug 15
Insufficient new directors Aug 10
DURECT Corporation to Report Q2, 2024 Results on Aug 13, 2024 Aug 08 See more updates
Third quarter 2024 earnings released: US$0.14 loss per share (vs US$0.11 loss in 3Q 2023) Nov 16
New major risk - Revenue and earnings growth Nov 14
DURECT Corporation to Report Q3, 2024 Results on Nov 13, 2024 Nov 07
Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.46 loss in 2Q 2023) Aug 15
Insufficient new directors Aug 10
DURECT Corporation to Report Q2, 2024 Results on Aug 13, 2024 Aug 08
DURECT Corporation, Annual General Meeting, Sep 25, 2024 Aug 05
DURECT Corporation to Report Q1, 2024 Results on May 13, 2024 May 09
DURECT Corporation to Report Q4, 2023 Results on Mar 27, 2024 Mar 21
DURECT Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Dec 24
DURECT Corporation to Report Q3, 2023 Results on Nov 13, 2023 Nov 10
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality Nov 08
Durect Corporation Announces Last Patient Last Visit in Phase 2B Ahfirm Trial of Larsucosterol in Alcohol-Associated Hepatitis Sep 09
DURECT Corporation to Report Q2, 2023 Results on Aug 09, 2023 Aug 04
DURECT Corporation Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis Jun 08
DURECT Corporation to Report Q3, 2022 Results on Nov 02, 2022 Oct 27
DURECT Corporation Announces Enrollment of More Than 200 of Planned 300 Patients in is Phase 2b AHFIRM Trial Oct 07
Innocoll Pharmaceuticals Limited and DURECT Corporation Announce U.S. Launch of POSIMIR Sep 27
DURECT Corporation Receives Approval from the Listing Qualifications Department of Nasdaq for an Additional 180-Day Grace Period, or Until February 6, 2023 Aug 10
Second quarter 2022 earnings released: US$0.051 loss per share (vs US$0.04 loss in 2Q 2021) Aug 06
DURECT Corporation to Report Q2, 2022 Results on Aug 04, 2022 Jul 28
DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer Jul 06
High number of new directors May 31
First quarter 2022 earnings released: US$0.048 loss per share (vs US$0.047 loss in 1Q 2021) May 06
No longer forecast to breakeven Apr 27
High number of new directors Apr 27
DURECT Corporation, Annual General Meeting, Jun 15, 2022 Apr 17
Independent Director recently bought €107k worth of stock Mar 17
No longer forecast to breakeven Mar 10
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 09
DURECT Corporation Announces Resignation of Michael Arenberg as Chief Financial Officer, Effective March 17, 2022 Mar 06
Durect Corporation Doses First European Patient in Phase 2B Ahfirm Study of Larsucosterol(Dur-928) in Severe Alcohol-Associated Hepatitis Mar 03
DURECT Corporation to Report Q4, 2021 Results on Mar 07, 2022 Mar 01
High number of new directors Jan 02
Forecast to breakeven in 2024 Jan 01
Third quarter 2021 earnings released: US$0.044 loss per share (vs US$0.046 loss in 3Q 2020) Nov 04
Second quarter 2021 earnings released: US$0.04 loss per share (vs US$0.073 profit in 2Q 2020) Jul 31
Forecast to breakeven in 2024 Jun 25
DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 Jun 24
DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH and in Hepatic Impairment At Upcoming International Liver Conference 2021 Jun 10
Durect Corporation Announces Publication of Dur-928'S Mechanism of Action Mar 10
DURECT Corporation to Report Q4, 2020 Results on Mar 04, 2021 Feb 26
DURECT Corporation Announces U.S. FDA Approval of POSIMIR® for Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression Feb 03
DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in Severe Alcohol-Associated Hepatitis Jan 28 DURECT Corporation Announces Board Changes
DURECT Corporation Announces Closing of LACTEL® Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 Million Jan 05
DURECT Corporation Announces Dur-928 Granted Fda Fast Track Designation for Treatment of Alcoholic Hepatitis Dec 18
DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience 2020 Nov 14
DURECT Corporation Appoints Norman Sussman as Chief Medical Officer Nov 11
DURECT Corporation Appoints Norman Sussman as Chief Medical Officer Nov 03
DURECT Corporation to Report Q3, 2020 Results on Nov 02, 2020 Oct 28
DURECT Corporation to Present Additional Safety and Efficacy Signals from Phase 1B Clinical Trial of Dur-928 in Nash Patients At the Liver Meeting Digital Experience 2020 Oct 06
DURECT Corporation Announces First Patient Dosed in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury Sep 24
Durect Corporation Announces the Study Design for the Phase 2B Ahfirm Clinical Trial of DUR-928 in Severe Alcoholic Hepatitis (AH) Patients Sep 23 Shareholder Returns DC8A DE Pharmaceuticals DE Market 7D 31.0% -2.5% -2.6% 1Y 104.1% -15.6% 6.9%
See full shareholder returns
Return vs Market: DC8A exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is DC8A's price volatile compared to industry and market? DC8A volatility DC8A Average Weekly Movement 13.6% Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: DC8A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: DC8A's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company’s lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals.
Show more DURECT Corporation Fundamentals Summary How do DURECT's earnings and revenue compare to its market cap? DC8A fundamental statistics Market cap €28.26m Earnings (TTM ) -€16.36m Revenue (TTM ) €8.24m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) DC8A income statement (TTM ) Revenue US$8.59m Cost of Revenue US$15.96m Gross Profit -US$7.36m Other Expenses US$9.70m Earnings -US$17.07m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.55 Gross Margin -85.70% Net Profit Margin -198.62% Debt/Equity Ratio 860.0%
How did DC8A perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 20:40 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources DURECT Corporation is covered by 15 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Mayank Mamtani B. Riley Securities, Inc. Irina Rivkind Koffler Cantor Fitzgerald & Co. James Molloy Caris & Company
Show 12 more analysts 
